GlaxoSmithKline: Multiple Myeloma trials
The registry lists 42 Multiple Myeloma studies with GlaxoSmithKline as lead sponsor. 6 are open to participants now and 30 have results posted.
Phase 1 23Phase 2 20Phase 3 8No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of CareNot yet recruitingNCT07742527Phase 1
- Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07614360Phase 2
- A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic ImpairmentNot yet recruitingNCT07609706Phase 1
- A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)RecruitingNCT07227311Phase 2
- A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)RecruitingNCT06679101Phase 3
- A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination TreatmentsRecruitingNCT05714839Phase 1/2
- Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMMActive, not recruitingNCT07217184Phase 1/2Results posted
- Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMMActive, not recruitingNCT07217119Phase 1/2Results posted
- Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMMActive, not recruitingNCT07150104Phase 1/2Results posted
- Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMMActive, not recruitingNCT07150091Phase 1/2Results posted
- Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMMActive, not recruitingNCT07084896Phase 1/2Results posted
- All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple MyelomaActive, not recruitingNCT06956170Phase 3Results posted
- Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple MyelomaActive, not recruitingNCT06868667Phase 3Results posted
- China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple MyelomaActive, not recruitingNCT06868654Phase 3Results posted
- Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMMTerminatedNCT06655818Phase 1/2Results posted
- Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMMTerminatedNCT06160609Phase 1/2Results posted
- Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT05064358Phase 2Results posted
- Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab MafodotinTerminatedNCT04549363Phase 3Results posted
- Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple MyelomaActive, not recruitingNCT04484623Phase 3Results posted
- A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal FunctionActive, not recruitingNCT04398745Phase 1Results posted
- Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple MyelomaActive, not recruitingNCT04246047Phase 3Results posted
- A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)CompletedNCT04177823Phase 1Results posted
- Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)Active, not recruitingNCT04162210Phase 3Results posted
- Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)Active, not recruitingNCT04126200Phase 1/2Results posted
- Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple MyelomaActive, not recruitingNCT04091126Phase 1Results posted
- Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)CompletedNCT03848845Phase 1/2Results posted
- An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma TreatmentsCompletedNCT03828292Phase 1Results posted
- To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)CompletedNCT03544281Phase 1/2Results posted
- A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 AntibodyCompletedNCT03525678Phase 2Results posted
- Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple MyelomaTerminatedNCT03168438Phase 1Results posted
- A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple MyelomaTerminatedNCT02082977Phase 1Results posted
- Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916CompletedNCT02064387Phase 1Results posted
- A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic MalignanciesCompletedNCT01943851Phase 2Results posted
- A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other CancersCompletedNCT01587703Phase 1Results posted
- Redirected Auto T Cells for Advanced MyelomaCompletedNCT01352286Phase 2Results posted
- A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple MyelomaTerminatedNCT00920556Phase 2Results posted
- A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic FunctionWithdrawnNCT04398680Phase 1
- Managed Access Program for Combination Treatment With Belantamab Mafodotin in Multiple MyelomaApproved for marketingNCT03763370
- Patient-Reported Outcome Measurement Information System (PROMIS) Physical FunctionCompletedNCT03351140
- A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor CancersCompletedNCT01476137Phase 1
- A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple MyelomaWithdrawnNCT01445587Phase 2
- Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT00315757Phase 2